343 related articles for article (PubMed ID: 26867931)
1. Comparative immunogenicity and structural analysis of epitopes of different bacterial L-asparaginases.
Pokrovsky VS; Kazanov MD; Dyakov IN; Pokrovskaya MV; Aleksandrova SS
BMC Cancer; 2016 Feb; 16():89. PubMed ID: 26867931
[TBL] [Abstract][Full Text] [Related]
2. [Cross-immunogenicity of various bacterial L-asparaginases].
D'iakov IN; Pokrovskiĭ VS; Sannikova EP; Bulushova NV; Pokrovskaia MV; Aleksandrova SS
Zh Mikrobiol Epidemiol Immunobiol; 2014; (6):100-4. PubMed ID: 25816523
[TBL] [Abstract][Full Text] [Related]
3. [Bacterial recombinant L-asparaginases: properties, structure and anti-proliferative activity].
Sokolov NN; Eldarov MA; Pokrovskaya MV; Aleksandrova SS; Abakumova OY; Podobed OV; Melik-Nubarov NS; Kudryashova EV; Grishin DV; Archakov AI
Biomed Khim; 2015; 61(3):312-24. PubMed ID: 26215408
[TBL] [Abstract][Full Text] [Related]
4. A structural in silico analysis of the immunogenicity of l-asparaginase from Escherichia coli and Erwinia carotovora.
Belén LH; Lissabet JB; de Oliveira Rangel-Yagui C; Effer B; Monteiro G; Pessoa A; Farías Avendaño JG
Biologicals; 2019 May; 59():47-55. PubMed ID: 30871932
[TBL] [Abstract][Full Text] [Related]
5. [Suppression of telomerase activity leukemic cells by mutant forms of Rhodospirillum rubrum L-asparaginase].
Pokrovskaya MV; Zhdanov DD; Eldarov MA; Aleksandrova SS; Veselovskiy AV; Pokrovskiy VS; Grishin DV; Gladilina JA; Sokolov NN
Biomed Khim; 2017 Jan; 63(1):62-74. PubMed ID: 28251953
[TBL] [Abstract][Full Text] [Related]
6. Studies on Deimmunization of Antileukaemic L-Asparaginase to have Reduced Clinical Immunogenicity--An in silico Approach.
Ramya LN; Pulicherla KK
Pathol Oncol Res; 2015 Sep; 21(4):909-20. PubMed ID: 25740072
[TBL] [Abstract][Full Text] [Related]
7. Mapping of B-cell epitopes in E. coli asparaginase II, an enzyme used in leukemia treatment.
Werner A; Röhm KH; Müller HJ
Biol Chem; 2005 Jun; 386(6):535-40. PubMed ID: 16006240
[TBL] [Abstract][Full Text] [Related]
8. Structural and functional insights into Erwinia carotovora L-asparaginase.
Papageorgiou AC; Posypanova GA; Andersson CS; Sokolov NN; Krasotkina J
FEBS J; 2008 Sep; 275(17):4306-16. PubMed ID: 18647344
[TBL] [Abstract][Full Text] [Related]
9. Rhizobium etli asparaginase II: an alternative for acute lymphoblastic leukemia (ALL) treatment.
Huerta-Saquero A; Evangelista-Martínez Z; Moreno-Enriquez A; Perez-Rueda E
Bioengineered; 2013; 4(1):30-6. PubMed ID: 22895060
[TBL] [Abstract][Full Text] [Related]
10. [Recombinant intracellular Rhodospirillum rubrum L-asparaginase with low L-glutaminase activity and antiproliferative effect].
Pokrovskaia MV; Pokrovskiĭ VS; Aleksandrova SS; Anisimova NIu; Adrianov RM; Treshchalina EM; Ponomarev GV; Sokolov NN
Biomed Khim; 2013; 59(2):192-208. PubMed ID: 23789346
[TBL] [Abstract][Full Text] [Related]
11. [Oligomerization of L-asparaginase from Erwinia carotovora].
Mezentsev IuV; Mol'nar AA; Gnedenko OV; Krasotkina IuV; Sokolov NN; Ivanov AS
Biomed Khim; 2006; 52(3):258-71. PubMed ID: 16898584
[TBL] [Abstract][Full Text] [Related]
12. Mutations in subunit interface and B-cell epitopes improve antileukemic activities of Escherichia coli asparaginase-II: evaluation of immunogenicity in mice.
Mehta RK; Verma S; Pati R; Sengupta M; Khatua B; Jena RK; Sethy S; Kar SK; Mandal C; Roehm KH; Sonawane A
J Biol Chem; 2014 Feb; 289(6):3555-70. PubMed ID: 24297177
[TBL] [Abstract][Full Text] [Related]
13. Cloning, expression and characterization of the recombinant Yersinia pseudotuberculosis L-asparaginase.
Pokrovskaya MV; Aleksandrova SS; Pokrovsky VS; Omeljanjuk NM; Borisova AA; Anisimova NY; Sokolov NN
Protein Expr Purif; 2012 Mar; 82(1):150-4. PubMed ID: 22226870
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of native or pegylated E. coli and Erwinia asparaginases assessed by ELISA and surface plasmon resonance (SPR-biacore) assays of IgG antibodies (Ab) in sera from patients with acute lymphoblastic leukemia (ALL).
Avramis VI; Avramis EV; Hunter W; Long MC
Anticancer Res; 2009 Jan; 29(1):299-302. PubMed ID: 19331165
[TBL] [Abstract][Full Text] [Related]
15. Optimizing asparaginase therapy for acute lymphoblastic leukemia.
Rizzari C; Conter V; Starý J; Colombini A; Moericke A; Schrappe M
Curr Opin Oncol; 2013 Mar; 25 Suppl 1():S1-9. PubMed ID: 23380829
[TBL] [Abstract][Full Text] [Related]
16. [Antitumor activity of L-asparaginase from Yersinia pseudotuberculosis].
Abakumova OIu; Podobed OV; Borisova AA; Sidoruk KV; Aleksandrova SS; Omel'ianiuk NM; Pokrovskaia MV; Kondakova LI; Sokolov NN
Biomed Khim; 2008; 54(6):712-9. PubMed ID: 19205431
[TBL] [Abstract][Full Text] [Related]
17. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase.
Billett AL; Carls A; Gelber RD; Sallan SE
Cancer; 1992 Jul; 70(1):201-6. PubMed ID: 1606543
[TBL] [Abstract][Full Text] [Related]
18. One-step purification and kinetic properties of the recombinant L-asparaginase from Erwinia carotovora.
Krasotkina J; Borisova AA; Gervaziev YV; Sokolov NN
Biotechnol Appl Biochem; 2004 Apr; 39(Pt 2):215-21. PubMed ID: 15032742
[TBL] [Abstract][Full Text] [Related]
19. Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase.
Figueiredo L; Cole PD; Drachtman RA
Expert Rev Hematol; 2016 Mar; 9(3):227-34. PubMed ID: 26765930
[TBL] [Abstract][Full Text] [Related]
20. A Randomized Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant Erwinia Asparaginase (JZP-458) in Healthy Adult Volunteers.
Lin T; Hernandez-Illas M; Rey A; Jenkins J; Chandula R; Silverman JA; Choi MR
Clin Transl Sci; 2021 May; 14(3):870-879. PubMed ID: 33278328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
